Clinical Trial Update: Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating dalotuzumab alone and in combination with ridaforolimus in pediatric patients with advanced solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Dalotuzumab (dalotuzumab)
• Ridaforolimus (ridaforolimus)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Solid Tumors | Phase 1 | Status: COMPLETED